Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chabiotech | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩858.8B | -35.5x | -1.37 | ₩15,360 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GC Cell | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩395.21B | -48.5x | 1.48 | ₩26,600 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Labgenomics | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩203.05B | -11.4x | 0.04 | ₩2,725 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DT CRO | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩82.49B | 34.3x | ₩6,350 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Dreamcis | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩80.08B | 23.7x | 1.01 | ₩3,235 | -3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biotoxtech | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩52.56B | -13.2x | 0.03 | ₩3,110 | -5.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
U2Bio | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩30.64B | 67.8x | ₩2,795 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
SLS Bio | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩29.7B | 28.2x | ₩2,280 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |